{"disease":{"id":"refractory-or-relapsed-non-hodgkin-s-lymphoma","name":"refractory or relapsed non hodgkin s lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04603872","title":"CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05422521","title":"Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}